Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 3 Dose Levels of NMD670 Over 21 Days in Adult Patients With AChR/MuSK-Ab+ Myasthenia Gravis

Next Previous
Search
Trial Profile

A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 3 Dose Levels of NMD670 Over 21 Days in Adult Patients With AChR/MuSK-Ab+ Myasthenia Gravis

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 06 Jan 2025 According to a NMD Pharma media release, the company has three ongoing global clinical trials investigating NMD670 including a Phase 2 study in adults living with spinal muscular atrophy (SMA) type 3, a Phase 2b study in gMG patients, and this Phase 2 CMT study, with data readout(s) occurring from 2H/2025 through 1H/2026.
  • 01 Oct 2024 According to NMD Pharma media release, company will present design, progress and improvement in QMG score and skeletal muscle function data from this phase 2b trial in an oral presentation during the Myasthenia Gravis Foundation of America (MGFA) Scientific Sessions, which will be held in Chatham Ballroom A in the Savannah Convention Center on Tuesday, 15 October from 8:00 am-12:00 pm.
  • 11 Jun 2024 Status changed from not yet recruiting to recruiting, according to NMD Pharma media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top